| Vol. 7.10 – 24 March, 2023 |
| |
|
|
| Scientists identified an epigenetic mechanism by which the early phase lipid redistribution from adipose tissue to the liver during regeneration impacted hepatocyte proliferation. [Nature Communications] |
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that the secreted pseudo serine protease PRSS35 functioned as a tumor suppressor in HCC. Mechanistically, they demonstrated that active PRSS35 was processed via cleavage by proprotein convertases. [Nature Communications] |
|
|
|
| Investigators examined the role of parathyroid hormone receptor-1 signaling in the activation of hepatic stellate cells and hepatic fibrosis. [Hepatology] |
|
|
|
| WD-repeat 6 (WDR6) deficiency in hepa1-6 cells drastically inhibited the growth and lung metastasis of orthotopically implanted tumors in immune-competent C57BL/6J mice. [EMBO Molecular Medicine] |
|
|
|
| Researchers reported that glycerol-3-phosphate acyltransferase 3 (GPAT3) played a key role in Kupffer cells (KCs) inflammation response. Their findings indicated that lipopolysaccharide-mediated inflammatory activation markedly increased lipid droplets accumulation in KCs. [Cell Death & Disease] |
|
|
|
| The expression of myocardial infarction-associated transcript (MIAT) was up-regulated during liver fibrosis. Silencing MIAT led to the suppression of hepatic stellate cell proliferation and collagen expression. [Communications Biology] |
|
|
|
| The authors found that the expression of KIFC3 was upregulated in HCC, and high KIFC3 expression was related to poor overall survival. [Experimental Cell Research] |
|
|
|
| Scientists proved that LncRNA MBNL1-AS1 increased the tripterine resistance of HCC cells at least partly by mediating miR-708-5p-related glycolysis. [Biotechnology and Genetic Engineering Reviews] |
|
|
|
| High-throughput RNA-sequencing analysis was conducted to identify the expression profile of circRNAs in HCC tissues and circ_0005218 was identified as one circRNA that significantly up-regulated in early recurrent HCC tissues. [Heliyon] |
|
|
|
|
|
| Scientists describe conserved and distinct pathogenic pathways highlighting therapeutic targets which may be of potential in both alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease, and those which are unique to each disease. [Hepatology] |
|
|
|
| The authors summarize the recent studies focusing on various components of the lipophagic machinery that can be modulated for their potential role as therapeutic agents against a wide range of liver diseases. [Molecular and Cellular Biochemistry] |
|
|
|
|
| 89bio, Inc. announced positive topline data from the Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with NASH. In the study, both the 44mg Q2W and 30mg QW doses met, with high statistical significance. [89bio, Inc.] |
|
|
|
|
| July 24 – 28, 2023 Boston, Massachusetts, United States |
|
|
|
|
|
| UmeÃ¥ University – UmeÃ¥, Sweden |
|
|
|
| Oslo University Hospital – Oslo, Norway |
|
|
|
| Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| Johns Hopkins University – Baltimore, Maryland, United States |
|
|
|
| University of Vermont – Burlington, Vermont, United States |
|
|
|
|